Trial Profile
A Feasibility Randomised Placebo-controlled Trial With Objective Outcome Measures to Evaluate the Efficacy of Biosimilar Rituximab in Musculoskeletal and Mucocutaneous Systemic Lupus Erythematosus
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Methylprednisolone
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms ROOTS
- 05 Apr 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2019).
- 30 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 30 Apr 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2020.